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Radiation risk to dialysis patients
To the Editor: We read with interest the article of Kinsella
et al.,1 who report that diagnostic X-ray could cause as much
as a 7% increase of cancer-related mortality in long-term
dialysis patients. We have considered some of the same data,
and we reach a more benign conclusion.
We agree that occupational radiation exposure of 75mSv
might increase cancer-related mortality by 7%.2 But the subjects
of that report were only 31 years old at ﬁrst exposure, and all
were employed. The average age of subjects starting dialysis
in the United States and Europe is over 60 years,3 and they have
co-morbidities that will be lethal before they might die of
radiation injury. The latency of radiation-related solid cancers is
more than 10 years and the risk decreases with age at exposure.4
As Kinsella et al. point out in their Table 1, their dialysis patients
who received the higher radiation doses were on average 61 years
old, and had an yearly death rate of 26%. These patients will not
survive long enough to develop radiation-related cancers.
It is possible that in children on dialysis who undergo
excessive X-ray studies, one might see radiation-induced
leukemia, because that cancer has a shorter latency.5 But this
has not been reported.
The immediate beneﬁts of diagnostic X-ray far outweigh
the theoretical long-term risk claimed by Kinsella et al.
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Support for a protective effect of
bilirubin on diabetic nephropathy
in humans
To the Editor: We read with great interest the article by Fujii
et al.1 in which they found that bilirubin (BIL) may protect
against diabetic nephropathy (DN) in experimental animals,
which could pave the way for novel antioxidant therapies for
DN. Given these tantalizing results in animal models, it would
be of interest to see whether BIL also exerts protection against
DN in humans. To this end, we investigated the association
between BIL and DN in a case–control study. Cases of DN were
deﬁned as duration of type 2 diabetes 45 years, albuminuria
4300mg per day, and presence of diabetic retinopathy
(n¼ 32). Controls were type 2 diabetic patients without
nephropathy, matched for age, sex, and duration of diabetes
(n¼ 32). Age was 64±9 years, 54% were male, and median
(interquartile range, IQR) duration of diabetes was 15 (10–20)
years. Urinary albumin concentration was 752 (239–1074)mg/l
in cases versus 3 (3–6)mg/l in controls (Po0.001). Estimated
glomerular ﬁltration rate (GFR) was 65±23ml/min per
1.73m2 in cases versus 84±15ml/min per 1.73m2 in controls
(Po0.001). BIL was 5.5±2.3mmol/l in cases versus 7.3±
3.3mmol/l in controls (P¼ 0.02).
Our data extend the ﬁndings of Fujii et al. with support for
a protective effect of BIL on DN in humans. Further
intervention studies are needed to explore the possibility of
using BIL-based novel antioxidant therapies to halt the
progression of DN.
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The Authors Reply: We appreciate Zelle et al.,1 for their
interest in our article2 and for raising some insightful
comments in their letter entitled ‘Support for a protective
effect of bilirubin on diabetic nephropathy in humans’.
As for the relationship between serum bilirubin and diabetic
nephropathy, we ﬁrst showed the lower prevalence of
vascular complications, including nephropathy in diabetic
patients with Gilbert syndrome, a congenital hyperbilirubi-
nemia, as well as reduced markers of oxidative stress and
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inﬂammation.3 Fukui et al.4 also reported that serum
bilirubin levels were associated with microalbuminuria and
subclinical atherosclerosis in patients with type 2 diabetes.
This letter by Zelle et al.1 further supported the relationship
between serum bilirubin and diabetic nephropathy in a
case–control study.
In the letter regarding the paper by Fukui et al.,4 Kassimatis
and Moutzouris5 claimed that it was unwarranted to discuss the
potential preventive and therapeutic application of bilirubin
or its diagnostic utility as a new risk factor for diabetic
nephropathy.5 In fact, these association studies do not
necessarily implicate the causative role of bilirubin in the
development of diabetic nephropathy. Therefore, we investi-
gated whether bilirubin may protect against diabetic nephro-
pathy in experimental animals in our article.2
Prospective studies are needed to conﬁrm its diagnostic
utility as a risk factor for diabetic nephropathy. In addition,
we agree that further intervention studies are needed to
explore the possibilities of compounds with similar properties
to bilirubin, which may represent a new class of therapeutic
agents that could protect against the development of diabetic
nephropathy.
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Circulating angiopoietin-1 could
be confounded by ex vivo
platelet activation
To the Editor: Reed et al.1 recently reported the relationship
between vascular endothelial growth factor (VEGF), angio-
poietin-1 (Ang-1), angiopoietin-2 (Ang-2), and renal as well
as cardiovascular disease progression in patients with
autosomal dominant polycystic kidney disease. Ang-1 and
Ang-2 are antagonistic ligands of their common receptor
Tie2. Unlike Ang-2, which is stored in endothelial cells, Ang-1
is not exclusively expressed by the vasculature; a high amount
of Ang-1 is also found in platelets. Thus, falsely high Ang-1
serum levels may result from ex vivo activation of platelets
upon clotting in serum tubes.2 The same is probably true
for vascular endothelial growth factor.3
Reed et al. found in the autosomal dominant polycystic
kidney disease population slightly elevated Ang-2 and
vascular endothelial growth factor (2–3 fold) serum levels
compared with those earlier reported in healthy individuals.
In contrast, mean Ang-1 levels in autosomal dominant
polycystic kidney disease patients were 35.52±21.03 ng/ml,
which is more than 20 times higher than the levels we and
others repeatedly detected in plasma from healthy subjects.2
However, we had earlier published similar falsely high Ang-1
levels in patients’ sera,4 unaware of the ex vivo release out
of platelets.
As Reed et al.1 performed all measurements in patients’
sera, one might question the validity and biological relevance
behind these ﬁndings (in particular the Ang-1/Ang-2 ratio).
In summary, it is possible that their results are confounded
by platelet-derived Ang-1.
A reliable way to quantify Ang-1 in a compartment-
speciﬁc way (i.e., the true circulatory fraction) would be
highly desirable for the design of future studies.
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The Authors Reply: We thank Drs David and Ku¨mpers1 for
their interest in our recent Kidney International publication.2
They point out that as angiopoietin-1 (Ang-1) is also found
in platelets, serum levels of Ang-1 may be falsely high due
to platelet activation. In our study, the most signiﬁcant
associations were between serum vascular endothelial growth
factor (VEGF) level with renal and cardiac structure (left
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